Cogent's Chronic Immune Disorder Drug Has Strong Potential To Become A Blockbuster: Analyst

benzinga.com/analyst-stock-ratings/analyst-color/25/07/46305144/cogents-chronic-immune-disorder-drug-has-strong-potential-to-become-a-blockbu

On Monday, Cogent Biosciences, Inc. (NASDAQ:COGT) said bezuclastinib showed meaningful clinical benefit for patients with non-advanced systemic mastocytosis.
The company said that its experimental drug reduced the symptoms of a chronic immune disorder called non-advanced systemic…

This story appeared on benzinga.com, 2025-07-08 18:26:44.
The Entire Business World on a Single Page. Free to Use →